Functionalized Gold Nanoparticles for Inhibition of Vascular Endothelial Growth Factor in Arthritic Patients

Abstract

The idea behind this study is the use of Nanotechnological approaches in treatment of arthritic patients through targeting of Vascular Endothelial Growth Factor A (VEGFA) as angiogenic factor. Anti-Vascular Endothelial Growth Factor A/Gold nanoparticles (anti-VEGFA /GNPs)conjugate have been prepared and applied to serum of Osteoarthritis (OA) and Rheumatoid Arthritis (RA) patients for scavenger of VEGFA antigen present in serum. The level of VEGFA in RA and OA patients has been estimated before and after incubation of serum of arthriticpatients with (anti-VEGFA /GNPs) anti-VEGFA/GNPs conjugate. It assumed that the antiVEGFA/GNPs conjugate bind with VEGFA antigen so it will inhibit proliferation and angiogenesis in serum of arthritic patients as primary treatment of arthritis. The characterization of both anti-VEGFA/GNPs conjugate and gold nanoparticles (GNPs) such as particle size, zeta potential (ZP), transmission electron microscopy (TEM) and FTIR were investigated. This anti-VEGFA/GNPs conjugate has been applied to “thirty three” serum samples of human patients with OA and RA in vitro. The Optimization of anti-VEGFA/GNPs gives that 100 ng/mL is an optimum concentration of anti-VEGFA/GNPs conjugate. It can decrease the level of VEGFA in serum of human patients upon incubation for 2 h rat room temperature. The anti-VEGFA/GNPs conjugate gives cure percent 59% and 62% in OA and RA patients ‘respectively through a single addition of anti-VEGFA/GNPs conjugate to serum that was validated by ELISA method. This technique open new modality and hope for OA and RA patients using novel nanotechnological approach.